<p>TIAA 信托国家协会根据最新提交给证券交易委员会的 13F 文件显示，在第一季度增持了百时美施贵宝（Bristol-Myers Squibb，NYSE:BMY - 免费报告）的股份，持股增长了 245.5%。该机构投资者在此期间额外增持了 298,026 股，持有这家生物制药公司的股份达 419,445 股。TIAA 信托国家协会在最新报告期结束时持有的百时美施贵宝股份价值 2274.7 万美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 警报：</p>
<ul>
<li>3 只高股息股票，现在收入，未来增长</li>
</ul>
<p>其他对冲基金最近也买卖了该公司的股票。挪威中央银行在第四季度购入了百时美施贵宝股份，价值约 15.60524 亿美元。M&amp;G Plc 在第一季度购入了百时美施贵宝股份，价值约 3.92608 亿美元。Pzena 投资管理公司在第一季度将其百时美施贵宝股份增加了 119.8%。Pzena 投资管理公司现在拥有 1229.3913 万股这家生物制药公司的股份，价值 6.66699 亿美元，比上一季度增持了 670.1097 万股。Van ECK Associates Corp 在第一季度将其百时美施贵宝股份增加了 97.2%。Van ECK Associates Corp 现在拥有 794.9173 万股这家生物制药公司的股份，价值 4.31084 亿美元，比上一季度增持了 391.8234 万股。最后，Primecap Management Co. CA 在第四季度将其百时美施贵宝股份增加了 14.6%。Primecap Management Co. CA 现在拥有 2353.4378 万股这家生物制药公司的股份，价值 12.07549 亿美元，比上一季度增持了 299.8228 万股。76.41% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些股票研究分析师最近对 BMY 股票发表了意见。William Blair 在 4 月 1 日星期一的研究报告中重申了对百时美施贵宝股票的 “市场表现” 评级。BMO Capital Markets 将百时美施贵宝的目标股价从 55.00 美元降至 48.00 美元，并在 4 月 26 日星期五的研究报告中给予该股票 “市场表现” 评级。StockNews.com 在 6 月 27 日星期四的研究报告中，将百时美施贵宝股票的评级从 “强热门” 调降至 “买入”。富国银行（Wells Fargo &amp; Company）将百时美施贵宝的目标股价从 51.00 美元上调至 52.00 美元，并在 4 月 18 日星期四的研究报告中给予该公司 “等权重” 评级。最后，巴克莱将百时美施贵宝的目标股价从 43.00 美元降至 41.00 美元，并在 7 月 10 日星期三的研究报告中给予该股票 “等权重” 评级。一位股票研究分析师给予该股票卖出评级，十三位给予持有评级，四位给予买入评级。根据 MarketBeat.com 的数据，百时美施贵宝目前的平均评级为 “持有”，公司的共识目标股价为 59.07 美元。</p>
<p><strong>阅读我们关于百时美施贵宝的最新研究报告</strong></p>
<h2>百时美施贵宝股票表现</h2>
<p>BMY 周五在午盘交易中上涨 0.25 美元，报 42.64 美元。该公司的股票交易量为 12,839,934 股，相比平均交易量 16,336,650 股。百时美施贵宝过去 12 个月的最低价为 39.35 美元，最高价为 65.38 美元。该股的市值为 864.4 亿美元，市盈率为-13.75，PEG 比率为 15.55，贝塔系数为 0.44。该公司的 50 天简单移动平均线为 41.68 美元，200 天简单移动平均线为 47.02 美元。该公司的流动比率为 1.11，速动比率为 0.99，负债权益比率为 2.99。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近公布了截至 4 月 25 日星期四的季度财报。这家生物制药公司报告本季度每股亏损 4.40 美元，超过了每股亏损 4.53 美元的共识预期 0.13 美元。百时美施贵宝的净资产回报率为 8.83%，净利润率为-13.50%。该公司本季度营收为 118.7 亿美元，高于分析师预期的 114.5 亿美元。去年同期，该公司每股收益为 2.05 美元。与去年同期相比，百时美施贵宝本季度的营收增长了 4.7%。研究分析师预计，百时美施贵宝今年将实现每股收益 0.55 美元。</p>
<h2>百时美施贵宝股息公告</h2>
<p>该公司最近宣布了季度股息，将于 8 月 1 日星期四支付。截至 7 月 5 日星期五的股东将获得每股 0.60 美元的股息。这代表年度股息为 2.40 美元，股息率为 5.63%。除息日为 7 月 5 日星期五。百时美施贵宝的派息比率目前为-77.42%。</p>
<h2>百时美施贵宝公司简介（免费报告）</h2>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。其产品涵盖血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者的中风/全身栓塞风险，以及用于 DVT/PE 的治疗；Opdivo，用于多种抗癌适应症，包括膀胱、血液、CRC、头颈、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓性白血病的治疗。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们比百时美施贵宝更喜欢的股票</li>
<li>投资商业服务股</li>
<li>为什么这只人工智能股票在科技抛售中上涨</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>投资者正在转向债券和小盘股：原因在这里</li>
<li>突破性股票：它们是什么以及如何识别</li>
<li>MarketBeat 周评 - 7/15 - 7/19</li>
</ul>
<p><strong>想看看其他对百时美施贵宝持有什么看法的对冲基金？</strong> 访问 HoldingsChannel.com 获取百时美施贵宝（NYSE:BMY - 免费报告）的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 揭秘：3 枚 CENT 加密货币将在 6 月 24 日爆发？（来自 True Market Insiders）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0"/></p>
<h2>现在是否值得投资$1,000 美元到百时美施贵宝？</h2>
<p>在考虑百时美施贵宝之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而百时美施贵宝不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

百时美施贵宝

<p>TIAA 信托国家协会在第一季度增持了百时美施贵宝 245.5% 的股份。其他对冲基金也购入了该公司的股票。几位股票研究分析师最近对 BMY 股票发表了意见。百时美施贵宝的股价目前为 42.64 美元。该公司最近披露了季度股息</p>

<p>TIAA Trust National Association increased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 245.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,445 shares of the biopharmaceutical company's stock after acquiring an additional 298,026 shares during the period. TIAA Trust National Association's holdings in Bristol-Myers Squibb were worth $22,747,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>TIAA 信托国家协会根据最新提交给证券交易委员会的 13F 文件显示，在第一季度增持了百时美施贵宝（Bristol-Myers Squibb，NYSE:BMY - 免费报告）的股份，持股增长了 245.5%。该机构投资者在此期间额外增持了 298,026 股，持有这家生物制药公司的股份达 419,445 股。TIAA 信托国家协会在最新报告期结束时持有的百时美施贵宝股份价值 2274.7 万美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 警报：</p>
<ul>
<li>3 只高股息股票，现在收入，未来增长</li>
</ul>
</div><p>Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,560,524,000. M&amp;G Plc purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $392,608,000. Pzena Investment Management LLC raised its stake in shares of Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company's stock worth $666,699,000 after purchasing an additional 6,701,097 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Bristol-Myers Squibb by 97.2% during the 1st quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock worth $431,084,000 after purchasing an additional 3,918,234 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Bristol-Myers Squibb by 14.6% during the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company's stock worth $1,207,549,000 after purchasing an additional 2,998,228 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金最近也买卖了该公司的股票。挪威中央银行在第四季度购入了百时美施贵宝股份，价值约 15.60524 亿美元。M&amp;G Plc 在第一季度购入了百时美施贵宝股份，价值约 3.92608 亿美元。Pzena 投资管理公司在第一季度将其百时美施贵宝股份增加了 119.8%。Pzena 投资管理公司现在拥有 1229.3913 万股这家生物制药公司的股份，价值 6.66699 亿美元，比上一季度增持了 670.1097 万股。Van ECK Associates Corp 在第一季度将其百时美施贵宝股份增加了 97.2%。Van ECK Associates Corp 现在拥有 794.9173 万股这家生物制药公司的股份，价值 4.31084 亿美元，比上一季度增持了 391.8234 万股。最后，Primecap Management Co. CA 在第四季度将其百时美施贵宝股份增加了 14.6%。Primecap Management Co. CA 现在拥有 2353.4378 万股这家生物制药公司的股份，价值 12.07549 亿美元，比上一季度增持了 299.8228 万股。76.41% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities research analysts have recently weighed in on BMY shares. William Blair reaffirmed a &#34;market perform&#34; rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Thursday, June 27th. Wells Fargo &amp; Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, April 18th. Finally, Barclays cut their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of &#34;Hold&#34; and a consensus price target of $59.07.</p>
<ul>
<li>Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore</li>
</ul>
<div class="lb-trans"><p>一些股票研究分析师最近对 BMY 股票发表了意见。William Blair 在 4 月 1 日星期一的研究报告中重申了对百时美施贵宝股票的 “市场表现” 评级。BMO Capital Markets 将百时美施贵宝的目标股价从 55.00 美元降至 48.00 美元，并在 4 月 26 日星期五的研究报告中给予该股票 “市场表现” 评级。StockNews.com 在 6 月 27 日星期四的研究报告中，将百时美施贵宝股票的评级从 “强热门” 调降至 “买入”。富国银行（Wells Fargo &amp; Company）将百时美施贵宝的目标股价从 51.00 美元上调至 52.00 美元，并在 4 月 18 日星期四的研究报告中给予该公司 “等权重” 评级。最后，巴克莱将百时美施贵宝的目标股价从 43.00 美元降至 41.00 美元，并在 7 月 10 日星期三的研究报告中给予该股票 “等权重” 评级。一位股票研究分析师给予该股票卖出评级，十三位给予持有评级，四位给予买入评级。根据 MarketBeat.com 的数据，百时美施贵宝目前的平均评级为 “持有”，公司的共识目标股价为 59.07 美元。</p>
</div><p><strong>Read Our Latest Research Report on Bristol-Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于百时美施贵宝的最新研究报告</strong></p>
</div><h2>Bristol-Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝股票表现</h2>
</div><p>BMY traded up $0.25 during midday trading on Friday, reaching $42.64. The company's stock had a trading volume of 12,839,934 shares, compared to its average volume of 16,336,650. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $65.38. The stock has a market cap of $86.44 billion, a P/E ratio of -13.75, a PEG ratio of 15.55 and a beta of 0.44. The company has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $47.02. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>BMY 周五在午盘交易中上涨 0.25 美元，报 42.64 美元。该公司的股票交易量为 12,839,934 股，相比平均交易量 16,336,650 股。百时美施贵宝过去 12 个月的最低价为 39.35 美元，最高价为 65.38 美元。该股的市值为 864.4 亿美元，市盈率为-13.75，PEG 比率为 15.55，贝塔系数为 0.44。该公司的 50 天简单移动平均线为 41.68 美元，200 天简单移动平均线为 47.02 美元。该公司的流动比率为 1.11，速动比率为 0.99，负债权益比率为 2.99。</p>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the firm earned $2.05 EPS. Bristol-Myers Squibb's revenue for the quarter was up 4.7% compared to the same quarter last year. Research analysts expect that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近公布了截至 4 月 25 日星期四的季度财报。这家生物制药公司报告本季度每股亏损 4.40 美元，超过了每股亏损 4.53 美元的共识预期 0.13 美元。百时美施贵宝的净资产回报率为 8.83%，净利润率为-13.50%。该公司本季度营收为 118.7 亿美元，高于分析师预期的 114.5 亿美元。去年同期，该公司每股收益为 2.05 美元。与去年同期相比，百时美施贵宝本季度的营收增长了 4.7%。研究分析师预计，百时美施贵宝今年将实现每股收益 0.55 美元。</p>
</div><h2>Bristol-Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百时美施贵宝股息公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.63%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb's payout ratio is presently -77.42%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 8 月 1 日星期四支付。截至 7 月 5 日星期五的股东将获得每股 0.60 美元的股息。这代表年度股息为 2.40 美元，股息率为 5.63%。除息日为 7 月 5 日星期五。百时美施贵宝的派息比率目前为-77.42%。</p>
</div><h2>Bristol-Myers Squibb Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>百时美施贵宝公司简介（免费报告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。其产品涵盖血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者的中风/全身栓塞风险，以及用于 DVT/PE 的治疗；Opdivo，用于多种抗癌适应症，包括膀胱、血液、CRC、头颈、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓性白血病的治疗。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Business Services Stocks Investing</li>
<li>Why This AI Stock is Rising Despite Tech Sell-Off</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Investors Are Moving into Bonds and Small Cap Stocks: Here's Why</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>MarketBeat Week in Review – 7/15 - 7/19</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五只我们比百时美施贵宝更喜欢的股票</li>
<li>投资商业服务股</li>
<li>为什么这只人工智能股票在科技抛售中上涨</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>投资者正在转向债券和小盘股：原因在这里</li>
<li>突破性股票：它们是什么以及如何识别</li>
<li>MarketBeat 周评 - 7/15 - 7/19</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对百时美施贵宝持有什么看法的对冲基金？</strong> 访问 HoldingsChannel.com 获取百时美施贵宝（NYSE:BMY - 免费报告）的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭秘：3 枚 CENT 加密货币将在 6 月 24 日爆发？（来自 True Market Insiders）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8484&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元到百时美施贵宝？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而百时美施贵宝不在名单上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

TIAA Trust National Association 增持了百时美施贵宝（NYSE:BMY）的股份